GTBP

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

GT Biopharma Inc

NASDAQ | GTBP

0.81

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$8.53M

Market Cap

-

P/E Ratio

-3.5

EPS

$4.10

52 Week High

$0.54

52 Week Low

HEALTHCARE

Sector

GTBP Chart

Recent Chart
Price Action

GTBP Technicals

Tags:

GTBP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$14M
Selling General And Administrative $8.6M
Research And Development $5.8M
Operating Expenses $14M
Investment Income Net -
Net Interest Income $402K
Interest Income $402K
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14M
Income Before Tax -$13M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$13M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$13M
Net Income -$13M

Revenue & Profitability

Earnings Performance

GTBP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.2M
Total Current Assets $4.2M
Cash And Cash Equivalents At Carrying Value $4M
Cash And Short Term Investments $4M
Inventory -
Current Net Receivables -
Total Non Current Assets $0
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $0
Other Current Assets $281K
Other Non Current Assets -
Total Liabilities $5.9M
Total Current Liabilities $5.9M
Current Accounts Payable $3.9M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations $0
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $2M
Other Non Current Liabilities -
Total Shareholder Equity -$1.7M
Treasury Stock -
Retained Earnings -$695M
Common Stock $2K
Common Stock Shares Outstanding $1.9M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $13M
Cashflow From Financing $3M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$13M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$14M
Selling General And Administrative $8.6M
Research And Development $5.8M
Operating Expenses $14M
Investment Income Net -
Net Interest Income $402K
Interest Income $402K
Interest Expense $0
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14M
Income Before Tax -$13M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$13M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$13M
Net Income -$13M

GTBP News

GTBP Profile

GT Biopharma Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

GT Biopharma Inc. is a pioneering clinical-stage biopharmaceutical firm headquartered in Beverly Hills, California, specializing in the development of cutting-edge immuno-oncology therapies. Leveraging its proprietary Tri-specific Killer Engager (TriKE) technology platform, the company aims to enhance immune responses against various cancers, thereby targeting and eliminating malignant cells. With a robust pipeline and a commitment to addressing significant unmet medical needs in oncology, GT Biopharma is strategically positioned to potentially transform treatment paradigms and improve outcomes for patients facing cancer. As the company advances through its clinical trials, it reflects a strong promise for innovation in the oncology landscape.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BIYA
+11.34%
$0.28
BYND
+2.00%
$1.04
TWOH
0.00%
$0.00
RUBI
-24.69%
$0.16
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
AFMD
-34.94%
$0.18
INTC
+5.13%
$38.70
APLD
+5.05%
$24.94
CLSK
+13.34%
$15.24
SNAP
+0.23%
$7.62
ADTX
+27.38%
$4.00
INHD
-6.51%
$0.21
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
NAKA
+7.20%
$0.49
KDLY
+7.20%
$0.49
ASST
+2.65%
$1.16
BMNU
+20.08%
$9.03
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
CHR
0.00%
$0.04
NEHC
+8.33%
$5.07
SMX
+209.42%
$53.84
PLUG
+1.01%
$2.00
NIO
+0.72%
$5.49
IREN
-0.30%
$48.30
DEFT
+20.86%
$1.68
ONDS
-3.80%
$7.92
MPW
+2.12%
$5.77
WULF
+5.49%
$15.65
WFC
+0.54%
$85.56
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCCS
+0.96%
$7.32
FL
-0.37%
$24.01
DAL
+3.41%
$64.27
CPRT
-0.79%
$38.75
FI
+0.06%
$60.80
AG
+8.35%
$14.63
VGFC
-1.90%
$0.05
VSA
-6.26%
$0.11
IVP
-9.92%
$0.12
CAN
+5.95%
$0.97
NEM
+5.21%
$90.52
WU
+0.58%
$8.67
CRCA
+19.42%
$4.39
CRCL
+7.47%
$78.07
UAA
+2.66%
$4.62
SVMH
-14.58%
$0.73
AGL
+3.94%
$0.66
SPGC
-8.21%
$0.16
CX
+1.43%
$10.57
TMC
+11.40%
$6.49
SGHC
-6.74%
$10.93
TGI
+0.61%
$26.01
FNGB
+2.90%
$21.28
AMZN
+1.06%
$231.61
ABVE
+4.21%
$2.74
BURU
+5.26%
$0.23
FRO
-1.95%
$23.52
SOFI
+1.64%
$28.96
PLTR
+0.53%
$166.65
F
+0.50%
$13.25
CRCG
+15.10%
$2.70
ZI
+0.51%
$9.67
NVTS
+8.33%
$9.03
ETHE
+3.36%
$24.86
BTG
+2.57%
$4.58
DVLT
+0.47%
$2.14
AZI
+4.59%
$0.06
OMGA
-10.81%
$0.14
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BIYA
+11.34%
$0.28
BYND
+2.00%
$1.04
TWOH
0.00%
$0.00
RUBI
-24.69%
$0.16
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
AFMD
-34.94%
$0.18
INTC
+5.13%
$38.70
APLD
+5.05%
$24.94
CLSK
+13.34%
$15.24
SNAP
+0.23%
$7.62
ADTX
+27.38%
$4.00
INHD
-6.51%
$0.21
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
NAKA
+7.20%
$0.49
KDLY
+7.20%
$0.49
ASST
+2.65%
$1.16
BMNU
+20.08%
$9.03
SAND
-6.04%
$12.12
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
CHR
0.00%
$0.04
NEHC
+8.33%
$5.07
SMX
+209.42%
$53.84
PLUG
+1.01%
$2.00
NIO
+0.72%
$5.49
IREN
-0.30%
$48.30
DEFT
+20.86%
$1.68
ONDS
-3.80%
$7.92
MPW
+2.12%
$5.77
WULF
+5.49%
$15.65
WFC
+0.54%
$85.56
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCCS
+0.96%
$7.32
FL
-0.37%
$24.01
DAL
+3.41%
$64.27
CPRT
-0.79%
$38.75
FI
+0.06%
$60.80
AG
+8.35%
$14.63
VGFC
-1.90%
$0.05
VSA
-6.26%
$0.11
IVP
-9.92%
$0.12
CAN
+5.95%
$0.97
NEM
+5.21%
$90.52
WU
+0.58%
$8.67
CRCA
+19.42%
$4.39
CRCL
+7.47%
$78.07
UAA
+2.66%
$4.62
SVMH
-14.58%
$0.73
AGL
+3.94%
$0.66
SPGC
-8.21%
$0.16
CX
+1.43%
$10.57
TMC
+11.40%
$6.49
SGHC
-6.74%
$10.93
TGI
+0.61%
$26.01
FNGB
+2.90%
$21.28
AMZN
+1.06%
$231.61
ABVE
+4.21%
$2.74
BURU
+5.26%
$0.23
FRO
-1.95%
$23.52
SOFI
+1.64%
$28.96
PLTR
+0.53%
$166.65
F
+0.50%
$13.25
CRCG
+15.10%
$2.70
ZI
+0.51%
$9.67
NVTS
+8.33%
$9.03
ETHE
+3.36%
$24.86
BTG
+2.57%
$4.58
DVLT
+0.47%
$2.14
AZI
+4.59%
$0.06
OMGA
-10.81%
$0.14
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.